As of 2026-02-04, 基于新抗原的治疗性疫苗及肿瘤相关抗原治疗性疫苗's data on the DeepSeek platform in the 抗肿瘤 DNA 疫苗新药研发 category shows: The overall mention rate is 0.00%, below the industry average by 10.2 percentage points, with significant room for improvement. The first mention rate is only 0.00%, it is recommended to enhance first-position exposure in AI model responses. Negative mention rate (0.00%) has exceeded positive (0.00%), it is recommended to immediately initiate reputation repair. AIGeo recommends combining the above data to formulate targeted brand monitoring strategies to further enhance brand visibility and reputation in the AI search ecosystem.
基于新抗原的治疗性疫苗及肿瘤相关抗原治疗性疫苗's Mention Rate is 0.00%, lower than 0.6% of competitors
基于新抗原的治疗性疫苗及肿瘤相关抗原治疗性疫苗's First Mention is 0.00%, lower than 0.9% of competitors
基于新抗原的治疗性疫苗及肿瘤相关抗原治疗性疫苗's Preferred Rate is 0.00%, lower than 100.0% of competitors
基于新抗原的治疗性疫苗及肿瘤相关抗原治疗性疫苗's Positive Rate is 0.00%, lower than 8.9% of competitors
基于新抗原的治疗性疫苗及肿瘤相关抗原治疗性疫苗's Negative Rate is 0.00%, higher than 96.3% of competitors
| Competitor | Mention Rate | First Mention | Preferred Rate | Positive Rate | Negative Rate | Actions |
|---|---|---|---|---|---|---|
| 基基于新抗原的治疗性疫苗及肿瘤相关抗原治疗性疫苗 (Current Brand) | 0% | 0% | 0% | 0% | 0% | View Details |
